Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523101 | 1.00 | FFAR1 (0.40) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL22185786 | 0.89 | LPL (0.40) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL23597018 | 0.87 | FFAR1 (0.44) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL406138 | 0.85 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL29506948 | 0.85 | AR (0.40) | FFAR1LPLLIPG | |
| SCHEMBL24023348 | 0.84 | LPL (0.37) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL22977685 | 0.84 | DGAT1 (0.38) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL19876295 | 0.84 | ALDH1A1 (0.37) | FFAR1LPLLIPG | |
| SCHEMBL22289520 | 0.83 | FFAR1 (0.42) | FFAR1LPLLIPGHIF1ADGAT1 | |
| SCHEMBL12989288 | 0.83 | FFAR1 (0.36) | FFAR1LPLLIPGHIF1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220056018-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | CAPULUS THERAPEUTICS, LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-13 | — | — | US | disclosed |
| EP-3917513-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | Capulus Therapeutics, LLC (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113631163-A | SREBP inhibitors comprising a thiophene central ring | 卡普勒斯疗法有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| EP-3038622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| EP-2970312-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015031650-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | CHAKRAVARTY SARVAJIT (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164596-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | FFAR1 810/4885LPL 450/4885LIPG 995/4885 |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | FFAR1 4727/4885LPL 4879/4885LIPG 4109/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | FFAR1 4727/4885LPL 4879/4885LIPG 4109/4885 |
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | FFAR1 4599/4885LPL 4682/4885LIPG 4459/4885 |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | FFAR1 430/4885LPL 1108/4885LIPG 212/4885 |
| US-20220056018-A1 | SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING | SREBF1, SREBF2, FABP1 | FFAR1 506/4885LPL 848/4885LIPG 1695/4885 |
| US-20220009906-A1 | ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS | GRK2, GRK3, GRK4 | FFAR1 603/4885LPL 1255/4885LIPG 1377/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | FFAR1 4649/4885LPL 3000/4885LIPG 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.